Business Context and Reporting Period
This Form 8-K is a current report filed by American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc.) on April 7, 2020, regarding an event that occurred on April 2, 2020. The company is incorporated in Nevada and is not an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is an amendment to the Company's Articles of Incorporation approved by the Board of Directors on March 12, 2020, and made effective on April 2, 2020, upon filing with the Nevada Secretary of State. The amendment increased the authorized shares of common stock (par value $0.001) from 20,000,000 to 100,000,000. Combined with the previously authorized 20,000,000 shares of preferred stock, the Company now has the authority to issue an aggregate of 120,000,000 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the capital structure amendment.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment with the Nevada Secretary of State.
- Confirm the total authorized share count is now 120,000,000 (100M common + 20M preferred).
- Review the attached Exhibit 3.1 for the full text of the Certificate of Amendment.
- Check subsequent filings for any actual issuance of shares against the newly authorized common stock.